NT
Neuphoria Therapeutics Inc
🇺🇸XNAS.NEUPUnited StatesHealthcare
$3.80USDunchanged 0.00 (0%)OpenDelayed4:18 PM
Price$3.800.00 (0%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US64136E1029
- CUSIP
- 64136E102
Company
- Employees
- 7
- Headquarters
- Burlington, United States
- Website
- https://www.neuphoriatx.com
- CEO
- Dr. Spyridon Papapetropoulos M.D., Ph.D.
Market
- Shares outstanding
- 5.4M
- Market cap
- $20.54M
Key dates
- Next earnings
- Oct 5, 2026
Highlights
- Market cap
- $20.43M
- EPS LTM
- -$5.26
- P/E LTM
- -0.77
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- -$10.47M-140.73%down year on year
- Net income
- -$28.48M-588.8%down year on year
- Gross margin
- 107.91%+23.82%up year on year
- Free cash flow
- $59.46M+9,027.12%up year on year
Other listings
This company is not listed on any other exchange we cover.
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.